Summary of declared interests from members of the GDG - Guideline for the prevention, diagnosis and treatment of infertility - NCBI Bookshelf An official website of the United States government Here's how you know The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Log in Show account info Close Account Logged in as: username Dashboard Publications Account settings Log out Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Bookshelf Search database Books All Databases Assembly Biocollections BioProject BioSample Books ClinVar Conserved Domains dbVar Gene Genome GEO DataSets GEO Profiles GTR Identical Protein Groups MedGen MeSH NLM Catalog Nucleotide OMIM PMC Protein Protein Clusters Protein Family Models PubChem BioAssay PubChem Compound PubChem Substance PubMed SNP SRA Structure Taxonomy ToolKit ToolKitAll ToolKitBookgh Search term Search Browse Titles Advanced Help Disclaimer NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. Guideline for the prevention, diagnosis and treatment of infertility [Internet]. Geneva: World Health Organization; 2025. Guideline for the prevention, diagnosis and treatment of infertility [Internet]. Show details Geneva: World Health Organization ; 2025. Contents Search term < Prev Next > Annex 4 Summary of declared interests from members of the GDG View in own window GDG member a Affiliation Nature of declared interest b Adam H. Balen Leeds Teaching Hospitals, Leeds, United Kingdom of Great Britain and Northern Ireland Shareholding, Consulting or Chair (CARE Fertility, Leeds, United Kingdom, and UK Innovation and Research Board); Advisory board membership, (Novo Nordisk Pharmaceuticals). Director and/or Partner (Balance Reproductive Health Ltd; Partner Balance Mind Ltd, and Balance Fertility Ltd); Trustee, Chair or Past Chair (British Fertility Society, NHS England IVF Pricing Development Expert Advisory Group); Fellows’ Representative, RCOG Council (until 2023). Guideline member (PCOS Global Guideline Group); Member, FIGO Steering Group on Anovulatory Infertility. No amounts declared for these roles. Jacky Boivin School of Psychology, Cardiff University, Cardiff, United Kingdom Non-monetary support £250 (ESHRE). Research support (£100 219, Merck Serono Ltd, paid to Cardiff University) non-interventional investigator led study on treatment planning. Consulting (£14 907, Ferring Pharmaceutical UK, United Kingdom, the Netherlands, Global). Public statements (total: £1750). Speaker fees (£26 107, Ferring Pharmaceutical, Merck, Gedeon-Richter, British Fertility Society, IVI-RMA). Barbara Collura The National Infertility Association (RESOLVE), Washington DC, United States of America (USA) Employment (Resolve); non-monetary support valued >US$ 1000; public statements. Ben Cohlen Isala Fertility Centre, Zwolle, the Netherlands Research support for clinic projects (grants) from Merck (US$ 30 000), Ferring (US$ 10 000), Gideon Richter (US$ 10 000). Christopher J. De Jonge University of Minnesota, Minneapolis, USA No interests declared. Sandro C. Esteves ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil Research support grant (Merck) US$ 90 000. Speaker fees (Merck, US$ 20 000; MedE.A./Med.E.A, US$ 9000). Non-monetary support valued at over US$ 1000 (Merck KGaA). Public statements. Cynthia Farquhar University of Auckland, Auckland, New Zealand No interest declared. Richard Kennedy Birmingham Women’s and Children’s NHS Foundation Trust, United Kingdom No interest declared. Klaudija Kordic Fertility Europe (Pan-European organisation representing patients’ associations), Evere, Belgium No interest declared. Linda Giudice UCSF School of Medicine, San Francisco, USA Investments in stocks (Merck), US$ 5000, (Pfizer) US$ 5000. Public statements as President of IFFS. Speaker fees (IBSA Pharma). Luca Gianaroli Reproductive Medicine Unit, S.I.S.Me.R., Bologna, Italy Employment and stakeholder in SISMER (up to 2024); consulting; non-monetary support valued at over US$ 1000; speaker fees; public statements; investments up to 2020 except in SISMER. Non-recurring fees from Merck, Theramex, InMed, MedThink. Consultant at Interdisciplinary Institute of Reproductive Medicine (IIRM) and at ART Fertility Clinic and Next Clinic (since 2025). Carin Huyser Steve Biko Academic Hospital, University of Pretoria, South Africa No interest declared. Dmitry Kissin Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, USA No interest declared. Tansu Kucuk Department of Obstetrics and Gynaecology, Acıbadem Maslak Hospital, Istanbul, Türkiye No interest declared. Nalini Mahajan Department of Reproductive Medicine, Mother and Child Hospital, New Delhi, India No interest declared. Ragaa Mansour The Egyptian IVF Center, Ma`adi, Cairo, Egypt No interest declared. Alfred Murage Aga Khan University Hospital, Nairobi, Kenya No interest declared. Willem Ombelet Genk Institute for Fertility Technology, Genk, Belgium No interest declared. Allan Pacey Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom Monetary support to employer valued at over US$ 1000 for consultancy/public speaking (Carrot Fertility [current], Cryos International [current], IBSA Institut Biochimique SA, Mealis Group). Several unpaid positions: Member of Advisory Board of Progress Educational Trust; Co-Chair, UKNEQAS Reproductive Sciences Advisory Committee; Member, Science Media Centre Advisory Board; Patron, Fertility Alliance (United Kingdom). Guido Pennings Department of Philosophy and Moral Sciences, Ghent University, Ghent, Belgium Non-monetary support valued at over US$ 1000 (Merck). Honorarium of speaker fees (Merck, US$ 2000; Teva Pharma, US$ 2000). Consulting fees (IVIRMA for membership of Ethics Committee, €20 000; Cryos Int. for membership of External Scientific Advisory Committee, €8000). Speakers fees (Gedeon Richter, €2000). Robert Rebar Homer Stryker School of Medicine, Western Michigan University, Kalamazoo, USA Employment (Lecturer WMU; editorial honorariums [NEJM Journal Watch Editor]) US$ 2500, honorarium (Contraception Journal deputy editor), US$ 3000. Honorarium (Associate editor Obs Gyn Clinical Alert), US$ 1600); consulting (BSMB for several clinical trials (Myovant; US$ 6000) up to 2020. Richard Reindollar Geisel School of Medicine, Dartmouth, New Hampshire, USA No interest declared. Roberta Rizzo University of Ferrara, Ferrara, Italy No interest declared. Rita Sembuya Joyce Fertility Support Centre, Kampala, Uganda No interest declared. Gamal Serour Al Azhar University, Cairo, Egypt No interest declared. Basil Tarlatzis Aristotle University of Thessaloniki, Thessaloniki, Greece Consulting; non-monetary support valued at >US$ 1000; research support for unrestricted research grants (Merk Serono) and Travel grants (MSD), honorariums (IBSA; Ferring - company sponsored speakers bureau); Advisory board (Ovascience). Carla Tatone University of L’Aquila, L’Aquila, Italy No interest declared. Lan N. Vuong University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam Research support/grants (2018–2020), valued at US$ 49 478 (Ferring). Non-monetary support valued at over US$ 1000 (Merck, for public education workshops). Speaker fees from Ferring (two conferences per year valued at US$ 500-1700), MSD (US$ 500–700), Merck (US$ 500–700) and ARD (US$ 3000). Travel support (including meeting registration fees) from Ferring, MSD and Merck. Marie Lena Windt De Beer Tygerberg Academic Hospital, Stellenbosch University, Cape Town, South Africa No interest declared. Cong Yali Health Science Centre, Peking University, Beijing, China No interests declared. a The following GDG members contributed to the initial part of the guideline but later stepped down: Lars Björndahl (Karolinska Institutet, Stockholm, Sweden), Roy Farquharson (Liverpool Women’s NHS Foundation Trust, Liverpool, United Kingdom), Anna Krawczack (Fertility Europe [Pan-European organisation representing patients’ associations], Evere, Belgium), Kersti Lundin (Sahlgrenska University Hospital, Gothenburg, Sweden) and Rebecca Sokol (Keck School of Medicine, University of Southern California, Los Angeles, USA). b The published interests exclude declared income from employment with public, regulatory, non-profit or nongovernmental organizations, academic institutions or universities, or public hospitals. © World Health Organization 2025. Sales, rights and licensing. To purchase WHO publications, see https://www.who.int/publications/book-orders . To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright . Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo ). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization ( http://www.wipo.int/amc/en/mediation/rules/ ). Bookshelf ID: NBK620437 Contents < Prev Next > Share Views PubReader Print View Cite this Page Guideline for the prevention, diagnosis and treatment of infertility [Internet]. Geneva: World Health Organization; 2025. Annex 4, Summary of declared interests from members of the GDG. PDF version of this title (4.0M) Other titles in this collection WHO Guidelines Approved by the Guidelines Review Committee Recent Activity Clear Turn Off Turn On Summary of declared interests from members of the GDG - Guideline for the preven... Summary of declared interests from members of the GDG - Guideline for the prevention, diagnosis and treatment of infertility Your browsing activity is empty. Activity recording is turned off. Turn recording back on See more... Follow NCBI Twitter Facebook LinkedIn GitHub NCBI Insights Blog Connect with NLM Twitter Facebook Youtube National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894 Web Policies FOIA HHS Vulnerability Disclosure Help Accessibility Careers NLM NIH HHS USA.gov